In 1999– 2003, several studies from Japan attempted to treat primary biliary cirrhosis with bezafibrate (13–18), and the results of these preliminary studies indicated that bezafibrate was effective in reducing ALP, γ-GT, and immunoglobulin M (IgM), with or without UDCA. Here, CD40LG is linked to primary biliary cholangitis.